Characterization of novel RHD alleles: relationship between phenotype, genotype, and trimeric architecture.

BACKGROUND: RH1 is one of the most clinically important blood group antigens in the field of transfusion and prevention of fetomaternal incompatibilities. New variant RHD alleles are regularly identified and their characterization is essential to ensuring patient safety. STUDY DESIGN AND METHODS: Blood samples with uncertain RhD phenotypes not resolved by our first-line SNaPshot assay were sequenced for all 10 RHD exons. RHD zygosity was investigated. Flow cytometry was performed to determine RhD antigen density and epitope pattern. RESULTS: Seven novel RHD alleles were identified. Six, that is, RHD(T55P), RHD(A85G), RHD(G132R), RHD(G132E), RHD(D403V), and DAR(T203A), resulted from nucleotide polymorphisms. The seventh, that is, RHD(S182WfsX46), resulted from a 4-bp deletion that led to a reading frame shift and the appearance of a premature stop codon. Study of RhD expression of the first five alleles at hemizygous state showed greatly reduced antigen densities ranging from 50 to 618 antigens per red blood cell (RBC). DAR(T203A) was classified as a partial D antigen with a weakened reactivity profile similar to that of DAR. As expected, no D antigen was detected on RBCs carrying the RHD(S182WfsX46) allele. In parallel, RhD expression of RHD(G336R)/weak D type 58, RHD(F410V), and suspected RHD(1-9)-CE was determined to be less than or equal to 50 antigens per RBC. RhAG/RhD(2) trimer model supports the observed phenotypes. CONCLUSION: Although the frequency of the new RHD alleles presented herein is low, their phenotypic and genotypic description adds to the repertoire of reported RHD alleles. These data can be useful for optimization of molecular screening tools.

Weak D and DEL alleles detected by routine SNaPshot genotyping: identification of four novel RHD alleles.

BACKGROUND: Molecular RHD blood group typing is very efficient for managing donors and patients carrying any of the various molecular types of weak D and DEL. The purpose of the work was to develop a multiplex polymerase chain reaction (PCR) SNaPshot assay for simultaneous detection of weak D and DEL alleles that are prevalent in Europeans, Africans, and Asians. STUDY DESIGN AND METHODS: Preliminary profiling was carried out on single-nucleotide polymorphisms (SNPs) associated with 13 prevalent RHD alleles, that is, weak D Types 1, 2, 3, 4.0, 4.0.1, 4.1, 4.2, 5, 11, 15, and 17; RHD(IVS3+1g>a); and RHD(K409K). Multiplex PCR was used to amplify six RHD regions encompassing 14 SNPs. Identification was obtained by incorporation of the complementary dye single base at the 3'-end of each probe-primer. A prospective analysis was then carried out on 152 blood samples from patients (n = 53) and donors (n = 88) with equivocal RhD serology and pregnant women (n = 11). RESULTS: After validation, our SNaPshot assay allowed direct genotyping of 82.9% of samples overall and 100% of samples harboring weak D Types 1, 2, 3, and 4.1 alleles. In the remaining 17.1% of samples overall, sequence investigation allowed accurate genotyping. In addition, four novel RHD alleles were identified, that is, RHD(S256P), RHD(L390L), RHD(F410V), and RHD(IVS4-2a>g). CONCLUSION: The SNaPshot assay described herein is a helpful supplementary tool for resolving doubtful RhD serology. By allowing accurate identification of weak D and DEL alleles this assay should allow better management of the donors and the patients genotyped weak D Types 1, 2, 3, and 4.1 who can receive D+ blood units.

Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population.

BACKGROUND: Anti-Fy(a) has been implicated in hemolytic transfusion reactions. However, not all Fy(a-) patients develop anti-Fy(a) after transfusion with 1 unit of blood [Fy(a+)]. This study was designed to identify HLA-DRB1 alleles associated with a predisposition to Fy(a) immunization after blood transfusion. STUDY DESIGN AND METHODS: To identify HLA-DRB1 alleles prone to immunization after blood transfusion or pregnancy, HLA-DRB1 genotyping using polymerase chain reaction with sequence-specific oligonucleotide nonradioactive probe/sequence-specific priming methods was performed on blood samples from 67 immunized patients and 200 unrelated controls from the same southern European population in a case-control retrospective study. RESULTS: Ninety-six percent of patients with anti-Fy(a) had at least one HLA-DRB1 04 or HLA-DRB1 15 allele compared to 34% of controls (p(c) < 0.001). Furthermore HLA-DRB1 04 and HLA-DRB1 1501 frequencies were significantly increased in Fy(a)-immunized patients (35% vs. 12%, p(c) < 0.001; and 30% vs. 19%, p(c) < 0.001, respectively). Among HLA-DRB1 04 allelic subtypes, DRB1 0401 and DRB1 0403 alleles were more strongly correlated with Fy(a) immunization (51% vs. 24% and 19% vs. 9%; p(c) < 0.001, respectively). CONCLUSIONS: This study indicated that HLA-DRB1 04 and DRB1 1501 are overrepresented in Fy(a)-immunized patients. The correlation between these alleles and Fy(a) immunization could be due to a particular presentation of the Fy(a) peptide in HLA-DRB1 molecules.

Erythrocyte-magnetized technology: an original and innovative method for blood group serology.

BACKGROUND: Erythrocyte-magnetized technology (EMT) is a new fully automated method for ABO-RH-K phenotyping and antibody detection. The magnetization of red cells avoids centrifugation and washing phases. This report describes the results of an evaluation of this new technology on its specific automated system. STUDY DESIGN AND METHODS: ABO-RH-K phenotyping was compared between EMT and a semiautomated routine method (liquid microplate for ABO-D and microcolumn system for RH-K) on 311 patients' samples. The overall performance of the new method was further assessed in daily routine on a total of 11,022 samples during 3 months in two different laboratories. Antibody detection was evaluated on 624 consecutive patients' samples and on 118 frozen samples containing specific antibodies in comparison with commercial microcolumn systems. RESULTS: Eight of 311 ABO-RH-K tests (2.6%) were not interpreted by EMT. Seven of them were weak antigen or reverse grouping reactions showing a negative result with the routine method. On a 3-month follow-up, 216 of 11,022 tests (1.96%) were not interpreted by the system, 75 percent of them being due to weak or mixed-field reactions. EMT was better in detecting ABO-D mixed-field reaction than routine microplate method. Detection of clinically significant antibodies was similar between EMT and microcolumn. In contrast, EMT detected a markedly lower rate of presumed nonsignificant antibodies. The system presents an overall high reliability. CONCLUSION: EMT is tailored to meet the needs of the transfusion service and represents an important advance in the field of immunohematology.

HLA-DRB1 polymorphism is associated with Kell immunisation.

K immunisation is observed in some polytransfused patients and pregnant women but does not occur in all cases of K incompatibility. This study analysed the role of genetic background in this selective response to K antigen by investigating HLA-DRB1 alleles associated with K immunisation in a southern European population. HLA-DRB1 genotyping was performed by polymerase chain reaction sequence-specific oligonucleotide/sequence-specific primer procedures in 54 K immunised patients and 200 healthy controls. The frequency of HLA-DRB1*11 was significantly higher in K immunised patients than healthy controls: 31 of 54 (57%) vs. 56 of 200 (28%) (P(c) < 0.001). In the remaining K immunised HLA-DRB1*11-negative patients, the frequency of HLA-DRB1*13 was increased: 14 of 23 (61%) vs. 49 of 144 in healthy controls (34%) (P < 0.02). The combined frequency of the two HLA-DRB1 alleles (HLA-DRB1*11 and HLA-DRB1*13) was 83% in K immunised patients when compared with 52% in healthy controls (P(c) < 0.001). K and k differ by a single amino acid T193 (M). The DRB1*11 and DRB1*13 alleles share a HLA-DRB1 gene sequence containing S in position 13, D in 70 and A in 74, and coding for the P4 pocket within the HLA-DR binding groove. This feature of the HLA-DRB1 gene could be involved in the K peptide presentation through a polymorphism ligand specific for the T193 (M) of K. In conclusion, this study demonstrated a high frequency of HLA-DRB1*11 or HLA-DRB1*13 alleles in K immunised patients, which could be due to specific K peptide presentation by HLA-DR molecules.

HLA-DRB1 alleles and Jk(a) immunization.

BACKGROUND: In transfusion medicine, anti-Jk(a) has been implicated in hemolytic transfusion reactions. Development of anti-Jk(a) after transfusion does not always occur after Jk(a-) patients receive at least 1 unit of Jk(a+) blood unit. This study was designed to identify HLA-DRB1 alleles associated with predisposition to Jk(a) immunization after blood transfusion or pregnancy. STUDY DESIGN AND METHODS: Genotyping by polymerase chain reaction and sequence-specific oligonucleotide probe nonradioactive hybridization/sequence-specific primers was performed in 20 Jk(a)-immunized patients and 200 controls from the same southern European population. RESULTS: Genotyping showed that HLA-DRB1*01 was significantly more frequent in Jk(a)-immunized patients than controls: 55 percent versus 17 percent (odds ratio [OR], 5.9; confidence interval [CI], 2.3-15.5; corrected p value<0.05). Because HLA-DRB1*0101, DRB1*0102, and DRB1*1001 share a common sequence in their B1 chain, that is, F in 13, R in 71, and A in 74, HLA genetic predisposition was analyzed by comparing patients and controls with respect to the distribution of F13/R71/A74-positive and -negative alleles. Results demonstrated greater positivity of the F13/R71/A74 sequence (DRB1*0101, *0102, or *1001) in patients than in controls: 65 percent versus 19.5 percent (OR, 7.7; CI, 2.9-20.5; p<0.001). CONCLUSION: In conclusion, HLA-DRB1*0101, DRB1*0102, and DRB1*1001, which share a common DRB1 sequence, appeared to be overrepresented in Jk(a)-immunized patients.

Adsorption of autoantibodies in the presence of LISS to detect alloantibodies underlying warm autoantibodies.

BACKGROUND: The safe transfusion of patients with warm autoimmune hemolytic anemia requires an efficient and time-saving assay to detect alloantibodies underlying autoantibodies. Methods used include RBCs treated with ZZAP reagent, proteolytic enzyme, or untreated RBCs in the presence of PEG. We propose a method using LISS, which presents some advantages over previous methods. STUDY DESIGN AND METHODS: We evaluated the effectiveness of autoantibody adsorption with papain-treated and untreated RBCs in the presence of LISS for removal of autoantibodies, without affecting alloantibodies. RESULTS: One-hundred twenty sera containing autoantibodies were adsorbed with our routine method, which uses papain-treated allogeneic RBCs. Seven-hundred twenty adsorptions (mean, 6 per sample) and 21,600 minutes (mean, 180 min per sample) were required to remove autoantibodies. Fifty sera were adsorbed with our routine method that uses papain-treated allogeneic RBCs in the presence of LISS. The number of adsorptions and the completion time were, respectively, 144 (mean, 2.9 per sample) and 2,880 minutes (mean, 57.6 min per sample). Twenty sera were evaluated with untreated autologous RBCs, in the presence of LISS; 58 adsorptions (mean, 2.9) and 1,160 minutes (mean, 58 min per sample) were required. Three adsorptions with antigen-negative allogeneic RBCs were performed on 8 sera containing alloantibodies with weak reactivity (anti-K [1], anti-D [1], anti-Fya[2], anti-S [2], anti-E [1], and anti-Jka[1]). Alloantibodies were detected with the LISS procedure with papain-treated and untreated RBCs and the routine papain method. Alloantibodies with weak reactivity, tested against the same antibody-detection RBCs, remained unchanged following adsorption of 5 sera. An anti-S, with very weak reactivity, was no longer detected, and an anti-Jka became weaker (1+), regardless of the procedure used. One anti-D became weaker only with the LISS adsorption method. CONCLUSION: Autoantibodies can be adsorbed more efficiently in the presence of LISS.